title: Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy.
abstract: Men treated for prostate cancer often have unexpected outcomes despite predictive models based on stage, grade and prostate-specific antigen (PSA). Previous results have indicated that nuclear morphometry can predict patient outcome in urologic malignancies. Application of this analytical method in prostate cancer treated with radiation therapy is limited. We have evaluated the predictive ability of nuclear morphometry in such patients. Histologic sections from 23 men with clinically localized adenocarcinoma of the prostate treated with radiation therapy were studied. Nuclear morphometric parameters were assessed using a previously described and validated system. Univariate and multivariate logistic regression analyses and a Cox proportional hazards model were used to assess the ability of nuclear morphometric parameters to predict recurrence and disease-free interval. Ten patients had no recurrence with median follow-up of 47. 5 months, while 13 had recurrence. Gleason grade was not predictive of treatment outcome. Pre-treatment PSA data, available for only 11 patients, were predictive of treatment outcome. Several nuclear morphometric parameters predicted recurrence, including upper quartile of suboptimal circle fit and upper quartile of feret-diameter ratio. A prognostic factor score incorporating these 2 parameters was derived, which predicted disease-free interval (p = 0.0014). Int. J. Cancer (Pred. Oncol.) 84:594-597, 1999.
authors.affiliation: Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Hurwitz
authors.forename: T L
authors.initials: TL
authors.lastname: DeWeese
authors.forename: E S
authors.initials: ES
authors.lastname: Zinreich
authors.forename: J I
authors.initials: JI
authors.lastname: Epstein
authors.forename: A W
authors.initials: AW
authors.lastname: Partin
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000473:pathology / Q000532:radiotherapy*; D000368:Aged; D000369:Aged, 80 and over; D002467:Cell Nucleus / Q000473:pathology; D002471:Cell Transformation, Neoplastic; D004247:DNA / Q000032:analysis; D018572:Disease-Free Survival; D006801:Humans; D007620:Karyometry; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000532:radiotherapy*; D012189:Retrospective Studies; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D004247:DNA